Global Radiofrequency Ablation Devices Market Growing at a CAGR of 11.5% from 2015 to 2019

Top Quote North America leads the global radiofrequency ablation devices market with a share of 45.3% in 2014 that translated into revenues worth US$ 1,421.8 million. End Quote
  • (1888PressRelease) October 06, 2015 - North America has the largest acceptance for radiofrequency ablation procedures in cardiac arrhythmia, gynecology, tumor management and pain management. The demand for RF based ablation devices is however slowly being replaced by other technologies such as ultrasound, cryoablation and microwave ablation technologies. Currently the United States has negligible market for hypertension since there has been no RF ablation device approved by the United States FDA. However, this is expected to change dramatically as Medtronic Inc, Boston Scientific and St. Jude Medical continue efforts to introduce the technology on a commercial level. The large hypertensive population will provide a strong revenue generation platform within the next 10 years.

    To read further, please visit:

    There are some global factors that are contributing to the steady growth of the RF ablation devices market. Rising incidence of tumors, arrhythmia and chronic pain across the world continues to ensure that the market grows steadily. The American Academy of Pain Medicine and American Society of Anesthesiologists suggest that chronic pain affects over 60 million people across the world. Pain is experienced due to trauma, sensory or nervous disorders, cancer, aging and a host of other reasons making it one of the most lucrative segments for introducing medical device for treatment. Devices such as renal denervation and RF uterine fibroid ablation have been available to Europeans far earlier than that in North America giving the region a major head-start in this market.

    Increasing number of EP labs in Europe is also a positive factor hinting a steady growth of the market. A significant challenge to the generators market is the fact that a large number of distributors and manufacturers install the ablation generators at no cost at all to the medical facility. This will continue to hinder the growth of the market. In several countries such as Germany, the practice of re-sterilizing single use catheters may further challenge growth due to which Europe has been termed as one of the slowest markets today.

    To read further, please visit:

    This report covers over 25 notable device manufacturers and highlights key players in each application segment while putting special emphasis on leaders of the RF ablation devices market such as Medtronic Inc (Covidien), Johnson & Johnson (Biosense Webster and DePuy Mitek), Boston Scientific, Stryker, St. Jude Medical, Arthrex and Haylard Health (former part of Kimberly Clark). Higher awareness of rarer applications such as endometrial ablation has also supplemented the growth of the RF ablation devices market in North America and Europe.

    Europe has shown particular resilience and leadership in approving renal denervation systems where the US FDA has remained unmovingly skeptical of the clinical outcomes. Nevertheless, the presence of most major RF technology companies in these regions and several new entrants in the market will ensure that these geographies continue to hold the controlling share.

  • FB Icon Twitter Icon In-Icon
Contact Information
  • John Whitmore
  • Sa-brc
  • 10685-B Hazelhurst Drive Suite 17411 Houston, TX 77043 United States
  • 77043
  • Voice: 18324263701
  • Visit our Site